Clinical trials: Eczema
Dermatitis, Atopic
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis
The purpose of this study is to assess the safety, tolerability, drug levels, drug effects, and impact on disease severity of BMS-986326 in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT06248814
- Testing
- BMS-986326
- Where
- 13 sites in Czechia, France and 3 more
- Volunteers
- 64 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis (AD), Eczema
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
- Trial name
- NCT06723405
- Testing
- EVO301
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 71 people
- Sponsor
- Evommune, Inc.
Psoriasis, Atopic Dermatitis
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.
- Trial name
- NCT06005792
- Testing
- XmAb27564
- Where
- 7 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Xencor, Inc.
Severe Atopic Dermatitis (AD)
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
This study is researching an approved drug called dupilumab (called "study drug"). Dupilumab is approved in the United States for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe…
- Trial name
- BUILD-PEDS (NCT07187089)
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
- Trial name
- NCT05984784
- Testing
- IMG-007
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Inmagene LLC
Atopic Dermatitis
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
- Trial name
- ADjoin (NCT04392154)
- Testing
- Lebrikizumab
- Where
- 321 sites in United States, Australia and 14 more
- Volunteers
- 1,153 people
- Sponsor
- Eli Lilly and Company
Chronic Hand Eczema
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema…
- Trial name
- NCT06004050
- Testing
- Delgocitinib, Vehicle cream
- Where
- 37 sites in China
- Volunteers
- 362 people
- Sponsor
- LEO Pharma
Atopic Dermatitis, Atopic
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease
- Trial name
- NCT06436183
- Testing
- Camoteskimab
- Where
- 35 sites in United States, Canada
- Volunteers
- 62 people
- Sponsor
- Apollo Therapeutics Ltd
Atopic Dermatitis
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
- Trial name
- NCT05186805
- Testing
- Tapinarof cream, 1%
- Where
- 10 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05014568
- Testing
- tapinarof cream, 1%, Vehicle cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 407 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05032859
- Testing
- tapinarof cream, 1%, vehicle cream
- Where
- 62 sites in United States, Canada
- Volunteers
- 406 people
- Sponsor
- Organon and Co
Atopic Dermatitis, Atopic Dermatitis Eczema
Topical ENS-002 for Atopic Dermatitis in Adults
The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.
- Trial name
- EnSync (NCT06469385)
- Testing
- ENS-002
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Concerto Biosciences
Atopic Dermatitis
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis.
- Trial name
- NCT05142774
- Testing
- Tapinarof cream, 1%
- Where
- 112 sites in United States, Canada
- Volunteers
- 728 people
- Sponsor
- Organon and Co
Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).
- Conditions
- Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD)
- Trial name
- CLEAR-AD1 (NCT06855745)
- Testing
- zabalafin
- Where
- 12 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Alphyn Biologics
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- NCT05906628
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose.
- Trial name
- NCT06444165
- Testing
- Lebrikizumab Pen
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Contact, Dermatitis
Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters
The study aims to evaluate and confirm the performance of 047 TD Dermatitis cream in the improvement of eczematous dermatitis and contact dermatitis, throughout a reduction in disease severity and symptoms.
- Conditions
- Dermatitis, Contact, Dermatitis, Dermatitis, Chronic, Dermatitis, Eczematous
- Trial name
- NCT07056569
- Testing
- 047_TD Dermatitis cream twice a day for 28 days
- Where
- 3 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Biokosmes Srl
Eczema, Atopic Dermatitis
Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic…
- Trial name
- STREAM-AD (NCT05131477)
- Testing
- Amlitelimab
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 390 people
- Sponsor
- Kymab Limited
Skin, Eczema
Eczeva Supplementation and Skin Health
Eczema, also known as atopic dermatitis, is a chronic skin condition characterized by inflamed, itchy, and often dry skin. It commonly affects individuals of all ages, although it frequently begins during childhood.
- Trial name
- NCT07049770
- Testing
- Eczeva supplementation
- Where
- Malaysia
- Volunteers
- 50 people
- Sponsor
- Zest Healthtech PLT
Atopic Dermatitis (Eczema)
The Effects of an Oral Prebiotic and an Oral Synbiotic Supplement in Combination With a Topical Lotion and Soap On Eczema
The purpose of this study is to examine the effects of 2 dietary supplements (an oral prebiotic and an oral synbiotic) in combination with a topical lotion, and an unscented soap on eczema severity, various skin measures (such as…
- Trial name
- NCT07041892
- Testing
- Prebiotic Supplement + Synbiotic Supplement + Topical Lotion + Unscented Soap
- Where
- Poland
- Volunteers
- 34 people
- Sponsor
- Codex Labs Corporation